- UNITY Biotechnology (UBX, Financial) reports a net loss of $7.3 million in Q1 2025, an increase from $5.8 million in Q1 2024.
- Cash position drops to $16.9M, with sufficient reserves to fund operations into Q4 2025.
- UBX1325 shows vision improvements comparable to aflibercept but misses primary endpoint at weeks 20-24, while achieving non-inferiority at week 36.
UNITY Biotechnology, Inc. (UBX) has announced its financial results for the first quarter of 2025, marked by a net loss of $7.3 million, up from $5.8 million during the same period last year. The increase in net loss is coupled with a cash reserve of $16.9 million as of March 31, 2025, showing a decline from $23.2 million at the end of 2024.
The company's lead drug candidate, UBX1325 (foselutoclax), is undergoing a Phase 2b ASPIRE study in diabetic macular edema (DME). The interim results at 36 weeks show non-inferiority to aflibercept, although the primary endpoint of statistical non-inferiority was not met at weeks 20 and 24. The full 36-week trial data is expected in the second quarter of 2025, which will be critical for future development strategies.
Despite financial challenges, including an increase in general and administrative expenses to $4.0 million, UNITY has managed to reduce its research and development expenses to $2.9 million. This reduction is mainly due to nearing the completion of the Phase 2 ASPIRE study. The company has indicated that its current cash reserves will suffice to fund operations into the fourth quarter of 2025, signaling the need for potential capital-raising activities.
